raav2tyf-pr1.7-hcngb3
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02599922)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclic nucleotide-gated cation channel beta-3Supplementation
supplementation - CNGB3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raav2tyf-pr1.7-hcngb3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02599922 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Applied Genetic Technologies Corp, National Eye Institute (NEI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Genetic Technologies Corp | For profit | 1 | 1 | 1 | 2016 |
| National Eye Institute (NEI) | Government | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1